跳至主要内容
临床试验/NCT05693012
NCT05693012招募中不适用

Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Myeloma: a Proof of Concept Study

Qiu Lugui1 个研究点 分布在 1 个国家目标入组 398 人开始时间: 2022年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
398
试验地点
1
主要终点
The sensitivity and specificity of a cfDNA methylation-based early detection modelfor multiple myeloma.

研究概览

简要总结

It is an observational, case-control study aimed at early-detection of multiple myeloma and constructing a prognostic model of multiple myeloma. The study will enroll approximately 398 participants including patients with multiple myeloma, patients with benign hematologic disorders and healthy participants.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The sensitivity and specificity of a cfDNA methylation-based early detection modelfor multiple myeloma.

时间窗: 12 months

次要结局

  • The specific cfDNA methylation landscape of multiple myeloma in China(12 months)
  • The sensitivity and specificity of a cfDNA methylation-based early detection model for multiple myeloma at different clinical stages.(12 months)
  • The performance of a cfDNA methylation-based prognostic model for multiple myeloma.(12 months)

研究者

发起方
Qiu Lugui
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Qiu Lugui

Director of lymphoma & myeloma center

Institute of Hematology & Blood Diseases Hospital, China

研究点 (1)

Loading locations...

相似试验